Compare OGN & VRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | VRE |
|---|---|---|
| Founded | 1923 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2020 | 1995 |
| Metric | OGN | VRE |
|---|---|---|
| Price | $6.11 | $18.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $11.75 | ★ $18.67 |
| AVG Volume (30 Days) | ★ 3.0M | 2.6M |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | 1.33% | ★ 1.70% |
| EPS Growth | N/A | ★ 420.00 |
| EPS | 0.72 | ★ 0.80 |
| Revenue | ★ $6,216,000,000.00 | $288,434,000.00 |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $1.67 | $2.87 |
| P/E Ratio | ★ $8.38 | $23.62 |
| Revenue Growth | N/A | ★ 6.40 |
| 52 Week Low | $6.03 | $13.69 |
| 52 Week High | $15.36 | $18.91 |
| Indicator | OGN | VRE |
|---|---|---|
| Relative Strength Index (RSI) | 29.92 | 79.48 |
| Support Level | N/A | $14.43 |
| Resistance Level | $7.87 | N/A |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 26.54 | 76.67 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.